You are here

Home › Listings › Life Sciences › Optima Medical Innovations Corp.

Optima Medical Innovations Corp.

Listing Exchange: 
CSE
Status: 
Suspended
Industry: 
Life Sciences
Symbol: 
OMIC
CSE Index: 
Currency: 

Optima Medical Innovations Corp. is a public company that delivers pathways to innovative, science-based health and wellness solutions. The Company is a leader in pain management, spanning from seed to patient. Built upon an extensive network of scientific and medical research, TOK is an advanced leader in the development, processing, and distribution of focused products and treatments for pain relief. Tree of Knowledge spans the globe with its multidisciplinary pain clinics, research partners, consumer CBD products, and education and advocacy programs – all working in harmony to bring health and wellness to the world while creating value for shareholders and partners.

You are here

Home

Optima Medical Innovations Corp. (OMIC)

SEDAR Information

Search form

Company Info

Address
209-5460 Yonge Street
Toronto, ON M2N 6K7
Canada
Phone
1-416-250-1812
Fax
1-416-250-8245
Email
[email protected]
Website
https://tokicorp.com
Listing date
Wednesday, July 4, 2018
Transfer Agent
Computershare Investor Services Inc.
Investor Relations
Ommid Faghani
Email
[email protected]
Auditor
Zeifmans LLP

Capitalization

Issued & Outstanding: 
47,500,131
Reserved for Issuance: 
5,645,679

Company Officers

Dr. Ommid John Faghani, Chairman, Chief Executive Officer
Scott Reeves, Director, Corporate Secretary
Dr. Ommid John Faghani, Interim Chief Financial Officer & President of TOK U.S. Operations
Kaivan Talachian, Director
Jacqueline Jordan, Director

News Releases

16/11/2021

Press Release dated October 1, 2021 - Shareholders Approve Corporate Changes at AGM

21/10/2021

Press Release dated October 20, 2021 Chu de Quebec Legal Action Dismissed

Bulletins

09/05/2022

2022-0504 – Suspensions (WIFI, CHAL, WLNS, EI, IKNK.U, KASH, FLYY, NI, YOOM, OMIC, ZOG)

Le 9 mai/May 2022

Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules.  Cease Trade Orders have been issued by one or more securities commissions. 

CSE Filings

Form 7 Monthly Progress Report (March) dated April 4, 2022

Form 7 Monthly Progress Report (February) dated March 4, 2022

Form 7 Monthly Progress Report (January) dated February 5, 2022

Form 7 Monthly Progress Report (December) dated January 5, 2022

Q3 MD&A September 30, 2021